Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Artiva Biotherapeutics (ARTV) has appointed Dr. Subhashis Banerjee as Chief Medical Officer, succeeding Dr. Thorsten Graef who will continue as a strategic advisor. Dr. Banerjee brings over 20 years of clinical development experience in autoimmune diseases, previously serving as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb and SVP of Clinical Development at VYNE Therapeutics.
The appointment strengthens Artiva's focus on developing their AlloNK® program for B-cell driven autoimmune diseases. Dr. Banerjee's expertise includes development of blockbuster therapies like Humira®, Taltz®, Orencia®, and Sotyktu®. The company has also expanded its development team with key appointments including David Moriarty as SVP of Clinical Operations, Benjamin Dewees as SVP of Regulatory Affairs, and Feng Xu as SVP of Biometrics.
Artiva Biotherapeutics (ARTV) ha nominato Dr. Subhashis Banerjee come Chief Medical Officer, succedendo al Dr. Thorsten Graef che continuerà come consulente strategico. Il Dr. Banerjee porta con sé oltre 20 anni di esperienza nello sviluppo clinico di malattie autoimmuni, avendo precedentemente ricoperto il ruolo di Responsabile dell'Area Malattia per la Reumatologia e la Dermatologia nello Sviluppo Globale presso Bristol Myers Squibb e SVP dello Sviluppo Clinico presso VYNE Therapeutics.
Questa nomina rafforza l'impegno di Artiva nello sviluppo del loro programma AlloNK® per le malattie autoimmuni guidate dalle cellule B. L'expertise del Dr. Banerjee include lo sviluppo di terapie di grande successo come Humira®, Taltz®, Orencia® e Sotyktu®. L'azienda ha anche ampliato il suo team di sviluppo con nomine chiave, tra cui David Moriarty come SVP delle Operazioni Cliniche, Benjamin Dewees come SVP degli Affari Regolatori e Feng Xu come SVP della Biometria.
Artiva Biotherapeutics (ARTV) ha nombrado al Dr. Subhashis Banerjee como Director Médico, sucediendo al Dr. Thorsten Graef, quien continuará como asesor estratégico. El Dr. Banerjee aporta más de 20 años de experiencia en el desarrollo clínico de enfermedades autoinmunes, habiendo sido anteriormente Jefe de Área de Enfermedad para Reumatología y Dermatología en el Desarrollo Global en Bristol Myers Squibb y SVP de Desarrollo Clínico en VYNE Therapeutics.
Esta designación refuerza el enfoque de Artiva en el desarrollo de su programa AlloNK® para enfermedades autoinmunes impulsadas por células B. La experiencia del Dr. Banerjee incluye el desarrollo de terapias exitosas como Humira®, Taltz®, Orencia® y Sotyktu®. La empresa también ha ampliado su equipo de desarrollo con nombramientos clave, incluyendo a David Moriarty como SVP de Operaciones Clínicas, a Benjamin Dewees como SVP de Asuntos Regulatorios y a Feng Xu como SVP de Biometría.
Artiva Biotherapeutics (ARTV)는 Dr. Subhashis Banerjee를 최고 의료 책임자로 임명하였으며, Dr. Thorsten Graef는 전략 고문으로 계속 활동할 예정입니다. Banerjee 박사는 자가면역 질환의 임상 개발 분야에서 20년 이상의 경험을 보유하고 있으며, 이전에는 Bristol Myers Squibb에서 류마티스 및 피부과 글로벌 개발의 질병 영역 책임자로, VYNE Therapeutics에서 임상 개발의 SVP로 근무했습니다.
이번 임명은 Artiva가 B세포 주도의 자가면역 질환을 위한 AlloNK® 프로그램 개발에 집중하는 데 힘을 실어줍니다. Banerjee 박사의 전문 분야에는 Humira®, Taltz®, Orencia®, Sotyktu®와 같은 블록버스터 치료제 개발이 포함됩니다. 회사는 또한 David Moriarty를 임상 운영 SVP로, Benjamin Dewees를 규제 업무 SVP로, Feng Xu를 생체계측 SVP로 포함한 주요 인사들을 통해 개발 팀을 확장했습니다.
Artiva Biotherapeutics (ARTV) a nommé Dr. Subhashis Banerjee en tant que Directeur Médical, succédant au Dr. Thorsten Graef qui continuera en tant que conseiller stratégique. Le Dr. Banerjee apporte plus de 20 ans d'expérience dans le développement clinique des maladies auto-immunes, ayant précédemment occupé le poste de Responsable de la Zone Maladie pour la Rhumatologie et la Dermatologie au Développement Global chez Bristol Myers Squibb et SVP du Développement Clinique chez VYNE Therapeutics.
Cette nomination renforce l'engagement d'Artiva à développer son programme AlloNK® pour les maladies auto-immunes à médiation B-cellulaire. L'expertise du Dr. Banerjee comprend le développement de thérapies à succès telles que Humira®, Taltz®, Orencia® et Sotyktu®. L'entreprise a également élargi son équipe de développement avec des nominations clés, notamment David Moriarty en tant que SVP des Opérations Cliniques, Benjamin Dewees en tant que SVP des Affaires Réglementaires et Feng Xu en tant que SVP des Biostatistiques.
Artiva Biotherapeutics (ARTV) hat Dr. Subhashis Banerjee zum Chief Medical Officer ernannt, der Dr. Thorsten Graef nachfolgt, der weiterhin als strategischer Berater tätig sein wird. Dr. Banerjee bringt über 20 Jahre Erfahrung in der klinischen Entwicklung von Autoimmunerkrankungen mit und war zuvor als Leiter des Krankheitsbereichs für Rheumatologie und Dermatologie in der globalen Entwicklung bei Bristol Myers Squibb sowie als SVP für klinische Entwicklung bei VYNE Therapeutics tätig.
Die Ernennung stärkt Artivas Fokus auf die Entwicklung ihres AlloNK® Programms für B-Zell-gesteuerte Autoimmunerkrankungen. Die Expertise von Dr. Banerjee umfasst die Entwicklung von Blockbuster-Therapien wie Humira®, Taltz®, Orencia® und Sotyktu®. Das Unternehmen hat auch sein Entwicklungsteam mit wichtigen Ernennungen erweitert, darunter David Moriarty als SVP für klinische Operationen, Benjamin Dewees als SVP für regulatorische Angelegenheiten und Feng Xu als SVP für Biometrie.
- Appointment of CMO with extensive experience in developing successful blockbuster autoimmune therapies
- Strategic expansion of development team with experienced executives in clinical operations, regulatory affairs, and biometrics
- AlloNK program shows promising B-cell depletion results from non-Hodgkin lymphoma treatments
- Enhanced expertise in autoimmune disease treatment development
- Previous CMO transitioning to advisory role, potentially affecting continuity in clinical development
- Company still in clinical-stage with no approved products
Dr. Banerjee’s appointment culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc. Dr. Banerjee will succeed Thorsten Graef, M.D., Ph.D., who will continue as a strategic advisor to the Company.
“We are pleased to welcome Dr. Banerjee to Artiva as we focus clinical development of our AlloNK® program on the treatment of B-cell driven autoimmune diseases. Dr. Banerjee, together with our recently appointed board member, Dr. Dan Baker, was a part of the early introduction of biologics for autoimmune diseases and reinforces the deep, longitudinal expertise in autoimmunity we have at Artiva,” said Fred Aslan, M.D., CEO of Artiva. “Importantly, we are excited to leverage Dr. Banerjee’s extensive experience in clinical development and regulatory approval of multiple blockbuster therapies for immune-mediated inflammatory and rheumatology indications, including Humira®, Taltz®, Orencia®, and Sotyktu®, to hone in on the rheumatology indications we believe AlloNK could bring relief to patients, and be administered in community settings worldwide.”
Dr. Aslan continued, “On behalf of the team, I wish to thank Dr. Graef for his extensive contributions to the Company and advancing our AlloNK oncology program to this stage. We look forward to his continued partnership in his new role as a strategic advisor.”
Dr. Banerjee added, “Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.”
Prior to joining Artiva, Dr. Banerjee served as SVP of Clinical Development at VYNE Therapeutics Inc., where he led the clinical development of BET inhibitors across many immune-mediated conditions. Prior to that, he served as Vice President and Disease Area Head of Rheumatology and Dermatology at BMS, where he played a key role in the development strategy of immunology assets across multiple platforms for several immune-mediated diseases. During his tenure at BMS, Dr. Banerjee served as the global lead for mid- to late-stage clinical development of Sotyktu (deucravacitinib), Orencia (abatacept) and clazakizumab (anti-IL-6 antibody) for the treatment of a variety of rheumatology indications, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephritis, idiopathic inflammatory myopathy (IIM) and Sjögren’s disease. Prior to working at BMS, Dr. Banerjee served as a global clinical program lead at Eli Lilly and Company on the clinical development of Taltz (ixekizumab, anti-IL-17 antibody) in RA, psoriasis, psoriatic arthritis and ankylosing spondylitis that led to marketing authorizations in the latter three indications. Earlier in his career, Dr. Banerjee supported the clinical development of Xeljanz® (tofacitinib) at Pfizer Inc., and early development activities of Humira (adalimumab) at AbbVie. Dr. Banerjee received his medical degree from Christian Medical College in Vellore, India, and he completed his residency in internal medicine at St. Vincent Hospital in Worcester, Massachusetts. He trained in immunology and autoimmune diseases at the Mayo Clinic and McGill University prior to joining the industry.
The appointment of Dr. Banerjee culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmunity and cell therapy that includes the following recent additions:
- David Moriarty, Ph.D., as SVP, Clinical Operations. Dr. Moriarty brings nearly 25 years of clinical research experience across cell therapy and autoimmune-focused indications. He was most recently at Kyverna Therapeutics, Inc., and prior to that, led global clinical operations and compliance for Horizon Therapeutics plc before Horizon’s acquisition by Amgen Inc., where he worked across multiple autoimmune and rare disease programs. Across his career, he has experience working on trials in a broad range of rheumatology indications, including RA, lupus and Sjögren’s disease.
- Benjamin Dewees as SVP, Regulatory Affairs. Mr. Dewees brings over 25 years of experience in regulatory affairs across cell therapy, gene therapy, autoimmune and rare disease programs. He was most recently at Kyverna Therapeutics, Inc., where he was the lead of the regulatory function. He spent most of his career at BioMarin Pharmaceutical Inc., supporting three separate product approvals, and several earlier stage companies over the last seven years across the cell and gene therapy space.
- Feng Xu as SVP, Biometrics. Mr. Xu brings over 20 years of experience in clinical development, including four successful global regulatory filings for commercial pharmaceutical products. Prior to Artiva, he served as the Head of Biometrics at IGM Biosciences, Inc., where he led biometrics for multiple early to mid-stage clinical trials in autoimmune and oncology indications, including RA and lupus. He began his career at Amgen Inc., where he served as the lead biostatistician for multiple pivotal clinical trials in inflammation, oncology and cardiovascular disease.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the “Company”) regarding the potential contributions of the recent hires to the Company, potential benefits, accessibility, effectiveness and safety of AlloNK®, and the Company’s ability to advance AlloNK® in autoimmune disease. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
Source: Artiva Biotherapeutics, Inc.
FAQ
What is the potential impact of AlloNK® program on ARTV's autoimmune disease treatment portfolio?
How does Dr. Banerjee's appointment in April 2025 strengthen ARTV's clinical development strategy?
What recent leadership changes has ARTV made to enhance its development team?
What are Dr. Banerjee's key achievements before joining ARTV?
